InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on INMD shares. TheStreet raised InMode from a "d+" rating to a "b-" rating in a report on Tuesday. Needham & Company LLC increased their target price on shares of InMode from $58.00 to $60.00 and gave the stock a "buy" rating in a report on Friday, July 29th. Robert W. Baird upped their price target on shares of InMode from $44.00 to $53.00 in a research report on Friday, July 29th. Canaccord Genuity Group decreased their price objective on shares of InMode from $50.00 to $40.00 and set a "buy" rating on the stock in a research report on Thursday, June 30th. Finally, Canaccord Genuity Group lowered their target price on shares of InMode from $50.00 to $40.00 and set a "buy" rating on the stock in a research note on Thursday, June 30th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, InMode has a consensus rating of "Buy" and a consensus price target of $63.00.
InMode Stock Up 2.6 %
Shares of INMD Stock opened at $36.98 on Friday. The company's fifty day simple moving average is $27.27 and its two-hundred day simple moving average is $32.43. InMode has a 52 week low of $20.60 and a 52 week high of $99.27. The stock has a market cap of $3.08 billion, a P/E ratio of 18.40 and a beta of 2.32.
InMode (NASDAQ:INMD - Get Rating) last issued its earnings results on Thursday, July 28th. The healthcare company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.51 by $0.08. InMode had a return on equity of 41.50% and a net margin of 42.66%. The firm had revenue of $113.55 million for the quarter, compared to analysts' expectations of $103.00 million. During the same period in the previous year, the firm posted $1.02 earnings per share. The business's revenue was up 30.0% compared to the same quarter last year.